We thank Ross et al. 1 for their additional comments on the definition of sensitivity with regard to minimal residual disease (MRD) in leukemia. Ross et al. 1 highlight two important issues that have to be addressed when estimating the lower limit of detection of MRD by a PCR assay: (1) the amount of DNA or RNA in each assay, and the number of replicates performed; and (2) the quality of the individual sample analysed.
We fully agree with these comments and the calculations that are provided by Ross et al. However, we would still challenge the statement that the standardized reporting of the estimated lower limit of detection of PCR assays for leukemia MRD is highly desirable. In clinical practice, we will always define a threshold of MRD that we use for therapeutic decisions, that is, if the MRD in a patient is above this threshold, we will perform a more intensive treatment than in another patient with an MRD below this threshold. 2 If we compare two different methods of monitoring MRD, the relevant question is to determine how reliably we can classify patients as having an MRD above or below this threshold. We have to determine the test sensitivity and specificity of the assays at this threshold.
The lower limit of detection of an MRD assay certainly provides some information about this assay, but the lower limit of detection alone does not tell how well this assay performs at a clinically relevant threshold. A very sound mathematical analysis of this issue was performed by Butturini et al.
